BRPI0506793A - métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5 - Google Patents

métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5

Info

Publication number
BRPI0506793A
BRPI0506793A BRPI0506793-6A BRPI0506793A BRPI0506793A BR PI0506793 A BRPI0506793 A BR PI0506793A BR PI0506793 A BRPI0506793 A BR PI0506793A BR PI0506793 A BRPI0506793 A BR PI0506793A
Authority
BR
Brazil
Prior art keywords
obesity
treatment methods
diabetes treatment
polypeptide
relates
Prior art date
Application number
BRPI0506793-6A
Other languages
English (en)
Inventor
Arnon Rosenthal
John C Lin
Jennifer R Stratton
Robert D Klein
Jaume Pons
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of BRPI0506793A publication Critical patent/BRPI0506793A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MéTODOS DE TRATAMENTO DA OBESIDADE OU DIABETES COM O USO DE NT-4/5. invenção refere-se a métodos para tratamento da obesidade, diabetes melito não insulino-dependente, síndrome metabólica e outras doenças relacionadas, por administração de um polipeptídeo NT-4/5. A invenção também se refere a composições farmacêuticas e kits compreendendo um polipeptídeo NT-4/5.
BRPI0506793-6A 2004-02-20 2005-02-22 métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5 BRPI0506793A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54639004P 2004-02-20 2004-02-20
PCT/US2005/005881 WO2005082401A1 (en) 2004-02-20 2005-02-22 Methods of treating obesity or diabetes using nt-4/5

Publications (1)

Publication Number Publication Date
BRPI0506793A true BRPI0506793A (pt) 2007-05-22

Family

ID=34910771

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506793-6A BRPI0506793A (pt) 2004-02-20 2005-02-22 métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5

Country Status (6)

Country Link
US (2) US20050209148A1 (pt)
EP (1) EP1720564A1 (pt)
JP (1) JP2007523196A (pt)
BR (1) BRPI0506793A (pt)
CA (1) CA2556923A1 (pt)
WO (1) WO2005082401A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007088479A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
JP2009528985A (ja) 2006-02-02 2009-08-13 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアゴニストを投与することにより望まれない体重減少または摂食障害を治療する方法
US7476405B2 (en) * 2006-02-23 2009-01-13 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
WO2011127304A2 (en) * 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5364768A (en) * 1987-07-07 1994-11-15 Farmitalia Carlo Erba S.R.L. Process for the preparation of penems
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5686579A (en) * 1988-06-21 1997-11-11 Hybrisens, Ltd. Use of antibody/antigen interactions to protect biologically active proteins and peptides
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
JPH03133378A (ja) * 1989-07-19 1991-06-06 Modrovich Ivan E 被験体を安定化させて液体中でのその生物学的活性を保存する方法
DE69121208T2 (de) * 1990-09-25 1997-01-23 Genentech Inc Neuer neurotropischer faktor
US6506728B2 (en) * 1990-09-25 2003-01-14 Genentech, Inc. Methods using a novel neurotrophic factor, NT-4
US6566091B1 (en) * 1990-09-25 2003-05-20 Genentech, Inc. Neurotrophic factor
ES2148144T3 (es) * 1990-11-20 2000-10-16 Dade Behring Marburg Gmbh Procedimiento para la estabilizacion de conjugados de enzima.
EP0666756B1 (en) * 1992-09-14 1999-11-24 Regeneron Pharmaceuticals, Inc. Method of producing analgesia using neurotrophins
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US20030191061A1 (en) * 1994-03-31 2003-10-09 Brewitt Barbara A. Treatment methods using homeopathic preparations of growth factors
US6024734A (en) * 1994-03-31 2000-02-15 Brewitt; Barbara A. Treatment methods using homeopathic preparations of growth factors
US6436908B1 (en) * 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
WO1995031183A1 (en) * 1994-05-16 1995-11-23 Washington University Cell membrane fusion composition and method
ES2204960T3 (es) * 1994-06-24 2004-05-01 Dade Behring Marburg Gmbh Procedimiento para la estabilizacion de moleculas sensibles a la hidrolisis.
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
EP0938499A1 (en) * 1996-07-19 1999-09-01 Amgen Inc. Analogs of cationic proteins
NZ335207A (en) * 1996-11-15 2000-09-29 Genentech Inc Process to isolate recombinant human neurotrophin using hydrophobic chromatography resin
KR20000070357A (ko) * 1997-01-23 2000-11-25 다께우찌 마사야쓰 당뇨병 치료제
US20030105057A1 (en) * 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL134536A0 (en) * 1997-08-29 2001-04-30 Vertex Pharma Compounds possessing neuronal activity and pharmaceutical compositions containing the same
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
EP1172113A4 (en) * 1999-04-16 2004-06-30 Sumitomo Pharma MEDICINE FOR AUTONOMOUS NEUROPATHIES
US6582945B1 (en) * 1999-06-16 2003-06-24 Boston Biomedical Research Institute Immunological control of β-amyloid levels in vivo
JP2003503482A (ja) * 1999-07-06 2003-01-28 バーテックス ファーマシューティカルズ インコーポレイテッド 環化アミノ酸誘導体
EP1200440A1 (en) * 1999-07-06 2002-05-02 Vertex Pharmaceuticals Incorporated Quinuclidine derivatives for treatment of neurological disorders
EP1196400A1 (en) * 1999-07-06 2002-04-17 Vertex Pharmaceuticals Incorporated Amino-alkyl derivatives
AU6205700A (en) * 1999-07-06 2001-01-22 Vertex Pharmaceuticals Incorporated Azo amino acid derivatives for the treatment of neurological diseases
AU6071400A (en) * 1999-07-06 2001-01-22 Vertex Pharmaceuticals Incorporated Cyclized amide derivatives
WO2001008685A1 (en) * 1999-07-30 2001-02-08 Vertex Pharmaceuticals Incorporated Acyclic and cyclic amine derivatives
CA2385929A1 (en) * 1999-10-29 2001-05-03 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Use of gdnf for treating corneal defects
US20030022840A1 (en) * 2000-02-18 2003-01-30 Michiko Kishino Drugs for ameliorating impaired glucose tolerance
US20030036512A1 (en) * 2000-03-06 2003-02-20 Tsutomu Nakagawa Leptin-resistance amerliorating agents
RU2004100701A (ru) * 2001-06-14 2005-06-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ациклические производные пиперазина и пиперидина, которые являются полезными для лечения повреждения нейронов
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US6712086B1 (en) * 2002-12-20 2004-03-30 Sidney T. Fails Above ground meter box
JP2009528985A (ja) * 2006-02-02 2009-08-13 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアゴニストを投与することにより望まれない体重減少または摂食障害を治療する方法

Also Published As

Publication number Publication date
US20090203610A1 (en) 2009-08-13
US20050209148A1 (en) 2005-09-22
JP2007523196A (ja) 2007-08-16
WO2005082401A1 (en) 2005-09-09
CA2556923A1 (en) 2005-09-09
EP1720564A1 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
CL2006003672A1 (es) Compuestos derivados de pirimido-[4,5-b]-oxazinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes mellitus y/u obesidad.
BRPI0516126A (pt) produtos farmacêuticos de polipeptìdeos intestinais vasoativos
WO2008055940A3 (en) Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
BRPI0511703B8 (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição
BRPI0519106A2 (pt) compostos, uso destes, processo para sua fabricaÇço, composiÇÕes farmacÊuticas, mÉtodo para o tratamento e/ou profilaxia de doenÇas que sço associadas com a dpp-iv
WO2004110375A3 (en) Combination therapy for the treatment of diabetes
CL2008002227A1 (es) Compuestos derivados de 4-[(8r)-4-amino-5-oxo-7,8-dihidrorimido[5,4-f][1,4]oxazepin-6(5h)-il]fenilo sustituido; su composicion farmaceutica; y uso de los compuestos en el tratamiento de la diabetes de tipo 2, utiles particularmente para tratar la obesidad.
CL2009000173A1 (es) Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros.
WO2007044591A3 (en) Vasoactive intestinal polypeptide pharmaceuticals
IL184554A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
CL2007001886A1 (es) Compuestos derivados de ureas de piperidina o pirrolidina; procedimiento de preparación; composición farmacéutica; y su uso como moduladores de la actividad de la 11ß-hidroxiesteroide deshidrogenasa tipo 1 (11ßhsd1) para tratar la obesidad, diabetes, resistenacia a la insulina, síndrome de cushing e hipertensión, entre otros.
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
DE602006010564D1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
CL2010000375A1 (es) Compuestos mimeticos de glucocorticoides derivados de hidroxialquilo sustituidos por heterociclos; procedimiento de preparacion; composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de un estado o trastorno seleccionado de diabetes tipo ii, obesidad, hipertension, entre otras (divisional de solicitud 585-03).
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
EA200701845A1 (ru) Рофлумиласт для лечения сахарного диабета
WO2006066747A8 (en) 4-aminopiperidine derivatives
BRPI0511367A (pt) uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo
CL2007001530A1 (es) Compuestos derivados de tiazol, inhibidores de fbpasa; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de diabetes mellitus tipo i, ii y iii, desequilibrio de glucosa en ayunas, desequilibrio en la tolerancia de la glucosa y complicaciones de la diabetes.
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
EA201170795A1 (ru) Антагонисты ccr2 группы 4-азетидинил-1-гетероарил-циклогексанола
NO20063103L (no) N-aryl-piperidinsubstituerte bifenyl karboksamider
BRPI0506793A (pt) métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6 ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.